Neutralizing and Complement-Fixing Antibodies for Japanese B Encephalitis Virus in Vaccinated U. S. Personnel in Japan

D. R. Ginder,M. Matumoto,R. Schlesinger,A. Sabin

DOI: https://doi.org/10.3181/00379727-65-15889

1947-05-01

Abstract:Summary Commercial Japanese B encephalitis mouse brain vaccine was administered to the occupation forces in Japan in 1946 by the triple-dose method, and the antibody response was studied in a group of men who received the first 2 doses of 1 cc each 4 to 5 days apart and the 3rd dose of 1 cc one month after the first dose. The vaccine used for the first dose had a 50% im-munogenic dose (ID50) of 0.028 cc by mouse assay, which is considerably less than the minimal required potency of 0.01 cc, and the lot used for the other 2 doses just fulfilled the minimal requirements with an ID50 of 0.0094 cc. The results in 20 Americans, aged 19 to 35, who were stationed in Tokyo and were without antibody or previous history of having received1 this vaccine, were as follows: (a) 15% had neutralizing antibodies 10 days after the 2nd dose, and 45% 10 days after the 3rd dose. (b) Only 2 men (10%) developed specific complement-fixing antibodies for the Japanese B virus, which appeared after the 2nd dose of vaccine. (c) Complement-fixing antibodies for the mouse brain component of the vaccine appeared in original serum dilutions of 1:2 to 1:4 in 35% after the 2nd dose and in 45% after the 3rd dose of vaccine. The antibody response in this group of Americans in Japan, vaccinated by the triple-dose method with commercial preparations, which either just fulfilled or were below the ID50 of 0.01 cc which is the minimal requirement of potency, was about the same after the 3rd dose as that previously obtained after the 2nd dose in a group of 25 Americans, of similar age in the U.S.A., who received 2 doses of 2 cc each, 3 days apart, of a freshly prepared vaccine with an ID50 of 0.0055 cc.